Dr. Massimo Collino is an Associate Professor of Pharmacology and Toxicology and Department of Drug Science and Technology at University of Turin at Italy. He is works as 2002 -2014 Assistant Professor of Pharmacology and Toxicology, Department of Drug Science and Technology, University of Turin. He is Fellow of the Italian Pharmacological Society, British Pharmacological Society, European Shock Society, European Biomedical Research Association. He works as Visiting Scientist at William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London (UK) from 09/2003 to 12/2004. He publish 50 full papers published in international journals with Impact Factor and 2 Book chapters 51 abstracts of National and International Congresses.
Dr. Massimo Collino’s is interested in the fields of Pathophysiology and the pharmacological therapy of diet-induced insulin resistance and the related cardiovascular risk factors, mainly organ-related ischemic events. Specifically, investigation of the pharmacological potential of selective ligands of the enzyme GSK-3beta, nuclear receptors PPAR and erythropoietin derivatives in in vivo models of ischemic diseases (myocardial infarction, stroke, acute kidney injury), shock (hemorrhagic and endotoxic shock) and diet-induced (mainly sugar-induced) dysmetabolism.
